Mohamed Tausif Siddiqui1, Mohammad Bilal2, Amandeep Singh1, Sarah Olivier-Cabrera3, Edward Lebovics3, Beth Schorr-Lesnick3, Brad Dworkin3, Donald F Kirby1. 1. Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio. 2. Department of Gastroenterology & Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 3. Department of Medicine, Division of Gastroenterology and Hepatology, New York Medical College, Valhalla, New York.
Abstract
INTRODUCTION: Cyclic vomiting syndrome (CVS) is a functional gastrointestinal disorder which leads to multiple hospitalizations and causes significant impairment of quality of life. Cannabis use is common in patients with CVS, and there are limited data on the national trends in the prevalence of its use in the United States. METHODS: We used the National Inpatient Sample (NIS) database from 2005 to 2014 and identified hospitalizations with a primary diagnosis of CVS by utilizing the International Classification of Diseases, 9th revision Clinical Modification (ICD-9 CM) coding system. The primary objective of the study was to analyze the prevalence and trends in cannabis use in CVS patients. We also assessed healthcare resource utilization associated with cannabis use. RESULTS: A total of 129 090 hospitalizations with a primary diagnosis of CVS were identified and included in the study. In the United States, the overall rate of cannabis use among these patients was 104 per 1000 hospitalizations (N = 13 460). Over the last decade, the prevalence of cannabis use increased by 10-fold, from 2.2% in 2005 to 21.2% in 2014. CONCLUSION: Our analysis of the national database suggests that nearly 1 in 5 CVS hospitalizations have concurrent cannabis use. This prevalence is significantly rising over the last decade, perhaps due to changing legislation and increased utilization of cannabis. Age younger than 35, male gender, African American and Native American race, personal history of alcohol abuse and tobacco use were some of the strongest predictors of cannabis use.
INTRODUCTION: Cyclic vomiting syndrome (CVS) is a functional gastrointestinal disorder which leads to multiple hospitalizations and causes significant impairment of quality of life. Cannabis use is common in patients with CVS, and there are limited data on the national trends in the prevalence of its use in the United States. METHODS: We used the National Inpatient Sample (NIS) database from 2005 to 2014 and identified hospitalizations with a primary diagnosis of CVS by utilizing the International Classification of Diseases, 9th revision Clinical Modification (ICD-9 CM) coding system. The primary objective of the study was to analyze the prevalence and trends in cannabis use in CVS patients. We also assessed healthcare resource utilization associated with cannabis use. RESULTS: A total of 129 090 hospitalizations with a primary diagnosis of CVS were identified and included in the study. In the United States, the overall rate of cannabis use among these patients was 104 per 1000 hospitalizations (N = 13 460). Over the last decade, the prevalence of cannabis use increased by 10-fold, from 2.2% in 2005 to 21.2% in 2014. CONCLUSION: Our analysis of the national database suggests that nearly 1 in 5 CVS hospitalizations have concurrent cannabis use. This prevalence is significantly rising over the last decade, perhaps due to changing legislation and increased utilization of cannabis. Age younger than 35, male gender, African American and Native American race, personal history of alcohol abuse and tobacco use were some of the strongest predictors of cannabis use.
Authors: Shaul Lev-Ran; Sameer Imtiaz; Benjamin J Taylor; Kevin D Shield; Jürgen Rehm; Bernard Le Foll Journal: Drug Alcohol Depend Date: 2011-12-03 Impact factor: 4.492
Authors: Madeline H Meier; Avshalom Caspi; Antony Ambler; HonaLee Harrington; Renate Houts; Richard S E Keefe; Kay McDonald; Aimee Ward; Richie Poulton; Terrie E Moffitt Journal: Proc Natl Acad Sci U S A Date: 2012-08-27 Impact factor: 11.205
Authors: Lennard Y W Lee; Laura Abbott; Bruce Mahlangu; Simon J Moodie; Simon Anderson Journal: Eur J Gastroenterol Hepatol Date: 2012-09 Impact factor: 2.566
Authors: Paris Charilaou; Kanishk Agnihotri; Pablo Garcia; Apurva Badheka; Douglas Frenia; Balaji Yegneswaran Journal: Am J Med Date: 2017-02-02 Impact factor: 4.965